Diamyd Medical-led ASSET program holds final precision-medicine screening conference

• Diamyd Medical will attend the ASSET program’s final conference, “Precision Medicine and the Future of Screening,” on Sept. 23, 2026, in Stockholm.
• Event will present results from a five-year project on AI-driven risk assessment for earlier detection of type 1 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diamyd Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 202609220310BITN____UKPR__SV_20260922-BIT-3587-0) on September 22, 2026, and is solely responsible for the information contained therein.